Sullivan MA, et al. - Patients with opioid use disorder treated with long-acting injection naltrexone (XR-naltrexone) or oral naltrexone in combination with behavioral therapy were compared regarding outcomes. In this open-label trial, they stratified 60 opioid-dependent adults, who completed inpatient opioid withdrawal and were transitioned to oral naltrexone, by the severity of opioid use (six or fewer bags vs more than six bags of heroin per day). These patients were randomly assigned (1:1) to continue treatment with oral naltrexone (N=32) or XR-naltrexone (N=28) for 24 weeks. The rate of treatment retention at 6 months was about double for patients receiving XR-naltrexone to that noted for those taking oral naltrexone. Results thereby favor using XR-naltrexone combined with behavioral therapy for patients seeking opioid withdrawal and support it as a nonagonist treatment for preventing relapse to opioid use disorder.